Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

c-mpl expression in hematologic disorders

D Bouscary1, C Prudhomme, B Quesnel

  • 1Department of Hematology, Hospital Cochin, Paris, France.

Leukemia & Lymphoma
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NCOA4 and ferritinophagy in hematological malignancies: a double-edged regulator of iron metabolism and cell fate.

Frontiers in oncology·2026
Same author

Biological Findings and Clinical Outcomes in Patients Treated With R-CHOP Plus High-Dose Methotrexate as First-Line Therapy in Large B-Cell Lymphoma With Testis Involvement.

European journal of haematology·2024
Same author

Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

British journal of haematology·2023
Same author

Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein.

Cell death discovery·2023
Same author

[GATA2 gene mutations: 3 cases].

La Revue de medecine interne·2022
Same author

Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2021
Same journal

Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019.

Leukemia & lymphoma·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
See all related articles

The c-mpl gene, crucial for blood cell development, shows elevated expression in certain leukemias like acute myeloid leukemia (AML) and myelodysplastic syndromes. This finding may help identify patient subgroups with poorer prognoses.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The c-mpl gene encodes a hematopoietic cytokine receptor subunit.
  • Its dysregulation is implicated in myeloproliferative disorders, as seen with the myeloproliferative leukemia virus (MPLV).
  • The c-mpl ligand's role in thrombocytopoiesis is under investigation.

Purpose of the Study:

  • To investigate c-mpl gene expression patterns in various human hematopoietic malignancies.
  • To correlate c-mpl expression levels with specific disease subtypes and clinical parameters.

Main Methods:

  • Northern blot analysis was employed to quantify c-mpl transcript levels.
  • Expression was assessed in normal bone marrow and diverse patient samples, including AML and myelodysplastic syndromes.

Related Experiment Videos

Main Results:

  • Elevated c-mpl expression was observed in 45% of acute myeloid leukemia (AML) cases.
  • c-mpl expression in AML correlated with CD34 positivity and unfavorable cytogenetics, identifying a poor-prognosis subgroup.
  • Increased c-mpl transcripts were found in chronic myelomonocytic leukemia (CMML) and refractory anemia with excess myeloblasts (RAEB/RAEBt), but not in refractory anemia (RA/RARS).

Conclusions:

  • c-mpl gene expression is significantly altered in specific myeloid malignancies.
  • Elevated c-mpl in AML defines a clinically relevant subgroup.
  • The role of c-mpl in myelodysplastic syndromes warrants further investigation.